Skip to main content
PMC home page
Heart logoLink to Heart
. 1999 Jul;82(1):40–46. doi: 10.1136/hrt.82.1.40

Abnormalities in liver function and coagulation profile following the Fontan procedure

R C van Nieuwenhuizen 1, M Peters 1, L Lubbers 1, M Trip 1, J Tijssen 1, B Mulder 1
PMCID: PMC1729092  PMID: 10377307

Abstract

OBJECTIVE—To investigate liver function and coagulation disorders in patients with a Fontan circulation at different time intervals after surgery.
DESIGN—Retrospective analysis of clinical data and cross sectional study relating liver function and coagulation profile to time since surgery, in 28 surviving patients after the modified Fontan procedure.
PATIENTS—20 patients (71%) with atriopulmonary anastomosis, seven (25%) with atrioventricular anastomosis, and one (4%) with total cavopulmonary connection. Follow up ranged from 2.0 to 21.8 years (mean 11.1).
RESULTS—Abnormal liver function tests, mainly reflecting cholestasis, were present in 21 patients who had a significantly longer follow up (p < 0.01). Protein synthesis was normal in almost all patients. Coagulation profile showed abnormalities in 22 patients. "Procoagulant" abnormalities—that is, decreased plasminogen and protein C activity—were found in 11 and five patients, respectively. The extent of these abnormalities was less in patients with a longer follow up. Anticoagulant abnormalities were factor V deficiency in 16 patients and factor VII deficiency in 17, resulting in a prolonged prothrombin time in 19 patients. Thirteen patients had both pro- and anticoagulant abnormalities. A prethrombotic state was present in five patients, with a significantly longer mean time interval since surgery (p = 0.05). Thus, although the individual procoagulant indices decreased with increasing time intervals since surgery, a prethrombotic state was found particularly in patients with a long term follow up.
CONCLUSIONS—Mild cholestasis was mainly present in Fontan patients with a long duration of follow up. Along with laboratory procoagulant abnormalities indicating a prethrombotic state, anticoagulant abnormalities were also present. The coagulation profile varied at different time intervals after surgery. Thus detailed evaluation should be performed regularly, and the use of anticoagulants should be considered in every patient. Long term prospective studies are needed to evaluate the individual fluctuations of coagulation profile over time following a Fontan procedure.


Keywords: Fontan procedure; coagulation; liver function; congenital heart disease

Full Text

The Full Text of this article is available as a PDF (143.8 KB).

Figure 1  .

Figure 1  

Open in a new tab

Relation between time since the first Fontan operation and different liver function variables. Solid line: linear correlation between the two variables; dotted line, upper limit of range of normal values; dashed line, lower limit of range of normal values. AST, aspartate aminotransferase; γGT, γ-glutamyltranspeptidase.

Figure 2  .

Figure 2  

Open in a new tab

Relation between time since the first Fontan operation and different coagulation status variables. Solid line, linear correlation between the two variables; dotted line, upper limit of normal values; dashed line, lower limit of normal values. APTT, activated partial prothrombin time; PT, prothrombin time.

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Behrendt D. M., Rosenthal A. Cardiovascular status after repair by Fontan procedure. Ann Thorac Surg. 1980 Apr;29(4):322–330. doi: 10.1016/s0003-4975(10)61479-8. [DOI] [PubMed] [Google Scholar]
  2. Bull K. The Fontan procedure: lessons from the past. Heart. 1998 Mar;79(3):213–214. doi: 10.1136/hrt.79.3.213. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Connolly S. J., Laupacis A., Gent M., Roberts R. S., Cairns J. A., Joyner C. Canadian Atrial Fibrillation Anticoagulation (CAFA) Study. J Am Coll Cardiol. 1991 Aug;18(2):349–355. doi: 10.1016/0735-1097(91)90585-w. [DOI] [PubMed] [Google Scholar]
  4. Cromme-Dijkhuis A. H., Henkens C. M., Bijleveld C. M., Hillege H. L., Bom V. J., van der Meer J. Coagulation factor abnormalities as possible thrombotic risk factors after Fontan operations. Lancet. 1990 Nov 3;336(8723):1087–1090. doi: 10.1016/0140-6736(90)92568-3. [DOI] [PubMed] [Google Scholar]
  5. Cromme-Dijkhuis A. H., Hess J., Hählen K., Henkens C. M., Bink-Boelkens M. T., Eygelaar A. A., Bos E. Specific sequelae after Fontan operation at mid- and long-term follow-up. Arrhythmia, liver dysfunction, and coagulation disorders. J Thorac Cardiovasc Surg. 1993 Dec;106(6):1126–1132. [PubMed] [Google Scholar]
  6. Davis C. A., Driscoll D. J., Perrault J., Greenwood D. H., Schaff H. V., Puga F. J., Danielson G. K., Feldt R. H. Enteric protein loss after the Fontan operation. Mayo Clin Proc. 1994 Feb;69(2):112–114. doi: 10.1016/s0025-6196(12)61035-0. [DOI] [PubMed] [Google Scholar]
  7. Driscoll D. J., Offord K. P., Feldt R. H., Schaff H. V., Puga F. J., Danielson G. K. Five- to fifteen-year follow-up after Fontan operation. Circulation. 1992 Feb;85(2):469–496. doi: 10.1161/01.cir.85.2.469. [DOI] [PubMed] [Google Scholar]
  8. Dunn G. D., Hayes P., Breen K. J., Schenker S. The liver in congestive heart failure: a review. Am J Med Sci. 1973 Mar;265(3):174–189. doi: 10.1097/00000441-197303000-00001. [DOI] [PubMed] [Google Scholar]
  9. Feldt R. H., Driscoll D. J., Offord K. P., Cha R. H., Perrault J., Schaff H. V., Puga F. J., Danielson G. K. Protein-losing enteropathy after the Fontan operation. J Thorac Cardiovasc Surg. 1996 Sep;112(3):672–680. doi: 10.1016/S0022-5223(96)70051-X. [DOI] [PubMed] [Google Scholar]
  10. Fontan F., Baudet E. Surgical repair of tricuspid atresia. Thorax. 1971 May;26(3):240–248. doi: 10.1136/thx.26.3.240. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Fontan F., Kirklin J. W., Fernandez G., Costa F., Naftel D. C., Tritto F., Blackstone E. H. Outcome after a "perfect" Fontan operation. Circulation. 1990 May;81(5):1520–1536. doi: 10.1161/01.cir.81.5.1520. [DOI] [PubMed] [Google Scholar]
  12. Girod D. A., Fontan F., Deville C., Ottenkamp J., Choussat A. Long-term results after the Fontan operation for tricuspid atresia. Circulation. 1987 Mar;75(3):605–610. doi: 10.1161/01.cir.75.3.605. [DOI] [PubMed] [Google Scholar]
  13. Hirschmann J. V. Pericardial constriction. Am Heart J. 1978 Jul;96(1):110–122. doi: 10.1016/0002-8703(78)90133-3. [DOI] [PubMed] [Google Scholar]
  14. Hoek J. A., Sturk A., ten Cate J. W., Lamping R. J., Berends F., Borm J. J. Laboratory and clinical evaluation of an assay of thrombin-antithrombin III complexes in plasma. Clin Chem. 1988 Oct;34(10):2058–2062. [PubMed] [Google Scholar]
  15. Jahangiri M., Ross D. B., Redington A. N., Lincoln C., Shinebourne E. A. Thromboembolism after the Fontan procedure and its modifications. Ann Thorac Surg. 1994 Nov;58(5):1409–1414. doi: 10.1016/0003-4975(94)91924-0. [DOI] [PubMed] [Google Scholar]
  16. Jahangiri M., Shore D., Kakkar V., Lincoln C., Shinebourne E. Coagulation factor abnormalities after the Fontan procedure and its modifications. J Thorac Cardiovasc Surg. 1997 Jun;113(6):989–993. doi: 10.1016/S0022-5223(97)70283-6. [DOI] [PubMed] [Google Scholar]
  17. Jonas R. A. Intracardiac thrombus after the Fontan procedure. J Thorac Cardiovasc Surg. 1995 Nov;110(5):1502–1503. doi: 10.1016/s0022-5223(95)70073-0. [DOI] [PubMed] [Google Scholar]
  18. Kaulitz R., Luhmer I., Bergmann F., Rodeck B., Hausdorf G. Sequelae after modified Fontan operation: postoperative haemodynamic data and organ function. Heart. 1997 Aug;78(2):154–159. doi: 10.1136/hrt.78.2.154. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Lemmer J. H., Coran A. G., Behrendt D. M., Heidelberger K. P., Stern A. M. Liver fibrosis (cardiac cirrhosis) five years after modified Fontan operation for tricuspid atresia. J Thorac Cardiovasc Surg. 1983 Nov;86(5):757–760. [PubMed] [Google Scholar]
  20. Matsuda H., Covino E., Hirose H., Nakano S., Kishimoto H., Miyamoto Y., Nishigaki K., Takano H., Ohtake S., Sakaki S. Acute liver dysfunction after modified Fontan operation for complex cardiac lesions. Analysis of the contributing factors and its relation to the early prognosis. J Thorac Cardiovasc Surg. 1988 Aug;96(2):219–226. [PubMed] [Google Scholar]
  21. Petersen P., Boysen G., Godtfredsen J., Andersen E. D., Andersen B. Placebo-controlled, randomised trial of warfarin and aspirin for prevention of thromboembolic complications in chronic atrial fibrillation. The Copenhagen AFASAK study. Lancet. 1989 Jan 28;1(8631):175–179. doi: 10.1016/s0140-6736(89)91200-2. [DOI] [PubMed] [Google Scholar]
  22. Tripodi A., Mannucci P. M. Markers of activated coagulation and their usefulness in the clinical laboratory. Clin Chem. 1996 May;42(5):664–669. [PubMed] [Google Scholar]
  23. Viganó S., Mannucci P. M., D'Angelo A., Rumi M. G., Viganó P., Del Ninno E., Cargnel A., Colombo M., Podda M. The significance of protein C antigen in acute and chronic liver biliary disease. Am J Clin Pathol. 1985 Oct;84(4):454–458. doi: 10.1093/ajcp/84.4.454. [DOI] [PubMed] [Google Scholar]
  24. Vukovich T., Teufelsbauer H., Fritzer M., Kreuzer S., Knoflach P. Hemostasis activation in patients with liver cirrhosis. Thromb Res. 1995 Feb 1;77(3):271–278. doi: 10.1016/0049-3848(95)91614-q. [DOI] [PubMed] [Google Scholar]
  25. Wilson D. G., Wisheart J. D., Stuart A. G. Systemic thromboembolism leading to myocardial infarction and stroke after fenestrated total cavopulmonary connection. Br Heart J. 1995 May;73(5):483–485. doi: 10.1136/hrt.73.5.483. [DOI] [PMC free article] [PubMed] [Google Scholar]
  26. van Teunenbroek A., Peters M., Sturk A., Borm J. J., Breederveld C. Protein C activity and antigen levels in childhood. Eur J Pediatr. 1990 Aug;149(11):774–778. doi: 10.1007/BF01957278. [DOI] [PubMed] [Google Scholar]

Articles from Heart are provided here courtesy of BMJ Publishing Group

RESOURCES